These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 17015999)

  • 21. Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: a multicenter, prospective, randomized, open-label study.
    West M; Boulanger BR; Fogarty C; Tennenberg A; Wiesinger B; Oross M; Wu SC; Fowler C; Morgan N; Kahn JB
    Clin Ther; 2003 Feb; 25(2):485-506. PubMed ID: 12749509
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group.
    Fink MP; Snydman DR; Niederman MS; Leeper KV; Johnson RH; Heard SO; Wunderink RG; Caldwell JW; Schentag JJ; Siami GA
    Antimicrob Agents Chemother; 1994 Mar; 38(3):547-57. PubMed ID: 8203853
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intravenous meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in hospitalized patients. Meropenem Serious Infection Study Group.
    Colardyn F; Faulkner KL
    J Antimicrob Chemother; 1996 Sep; 38(3):523-37. PubMed ID: 8889726
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Non-inferiority Pilot Study Comparing the Clinical Efficacy and Safety of Generic Wide-spectrum Antibiotic Use in Septic Oncology Patients.
    Araya I; Fasce G; Núñez E; Opazo JL; Saez E; Hurtado V; Contreras S; Quiñones LA
    Drug Res (Stuttg); 2015 Dec; 65(12):635-9. PubMed ID: 25811220
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prospective, randomized, study of ampicillin-sulbactam versus moxifloxacin monotherapy for the treatment of community-acquired complicated intra-abdominal infections.
    Chen CW; Ming CC; Ma CJ; Shan YS; Yeh YS; Wang JY
    Surg Infect (Larchmt); 2013 Aug; 14(4):389-96. PubMed ID: 23859673
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections.
    Sims M; Mariyanovski V; McLeroth P; Akers W; Lee YC; Brown ML; Du J; Pedley A; Kartsonis NA; Paschke A
    J Antimicrob Chemother; 2017 Sep; 72(9):2616-2626. PubMed ID: 28575389
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early switch therapy from intravenous sulbactam/ampicillin to oral garenoxacin in patients with community-acquired pneumonia: a multicenter, randomized study in Japan.
    Kohno S; Yanagihara K; Yamamoto Y; Tokimatsu I; Hiramatsu K; Higa F; Tateyama M; Fujita J; Kadota J
    J Infect Chemother; 2013 Dec; 19(6):1035-41. PubMed ID: 23695232
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Imipenem/cilastatin (1.5 g daily) versus meropenem (3.0 g daily) in patients with intra-abdominal infections: results of a prospective, randomized, multicentre trial.
    Basoli A; Meli EZ; Mazzocchi P; Speranza V
    Scand J Infect Dis; 1997; 29(5):503-8. PubMed ID: 9435041
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia.
    Freire AT; Melnyk V; Kim MJ; Datsenko O; Dzyublik O; Glumcher F; Chuang YC; Maroko RT; Dukart G; Cooper CA; Korth-Bradley JM; Dartois N; Gandjini H;
    Diagn Microbiol Infect Dis; 2010 Oct; 68(2):140-51. PubMed ID: 20846586
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rapid imipenem/cilastatin desensitization for multidrug-resistant Acinetobacter pneumonia.
    Gorman SK; Zed PJ; Dhingra VK; Ronco JJ
    Ann Pharmacother; 2003 Apr; 37(4):513-6. PubMed ID: 12659606
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study.
    Zanetti G; Bally F; Greub G; Garbino J; Kinge T; Lew D; Romand JA; Bille J; Aymon D; Stratchounski L; Krawczyk L; Rubinstein E; Schaller MD; Chiolero R; Glauser MP; Cometta A;
    Antimicrob Agents Chemother; 2003 Nov; 47(11):3442-7. PubMed ID: 14576100
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized comparative trial of imipenem/cilastatin versus aminoglycoside plus amoxycillin plus clindamycin in the treatment of severe intra- and post-operative infections.
    Cakmakci M; Stern A; Schilling J; Christen D; Roggo A; Geroulanos S
    Drugs Exp Clin Res; 1993; 19(5):223-7. PubMed ID: 8174495
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Domestic imipenem cilastatin sodium for the treatment of severe aspiration pneumonia, a curative effect observation].
    Yin HY; Ye XL; Zhang R; Zhu YF
    Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2012 Oct; 24(10):628-31. PubMed ID: 23040783
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized multicenter trial of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of severe intra-abdominal infections. Swedish Study Group.
    Eklund AE; Nord CE
    J Antimicrob Chemother; 1993 Jan; 31 Suppl A():79-85. PubMed ID: 8383657
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ampicillin/sulbactam: current status in severe bacterial infections.
    Rafailidis PI; Ioannidou EN; Falagas ME
    Drugs; 2007; 67(13):1829-49. PubMed ID: 17722953
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rational antibiotic therapy and the position of ampicillin/sulbactam.
    Lode HM
    Int J Antimicrob Agents; 2008 Jul; 32(1):10-28. PubMed ID: 18539004
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of severe nosocomial pneumonia: a prospective randomised comparison of intravenous ciprofloxacin with imipenem/cilastatin.
    Torres A; Bauer TT; León-Gil C; Castillo F; Alvarez-Lerma F; Martínez-Pellús A; Leal-Noval SR; Nadal P; Palomar M; Blanquer J; Ros F
    Thorax; 2000 Dec; 55(12):1033-9. PubMed ID: 11083889
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A multicenter comparative study of meropenem and imipenem/cilastatin in the treatment of complicated urinary tract infections in hospitalized patients.
    Cox CE; Holloway WJ; Geckler RW
    Clin Infect Dis; 1995 Jul; 21(1):86-92. PubMed ID: 7578765
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biapenem versus imipenem/cilastatin in the treatment of complicated intra-abdominal infections: report from a Swedish Study Group.
    Brismar B; Akerlund JE; Sjöstedt S; Johansson C; Törnqvist A; Bäckstrand B; Bång H; Andåker L; Gustafsson PO; Darle N; Angerås M; Falk A; Tunevall G; Kasholm-Tengve B; Skau T; Nyström PO; Gasslander T; Hagelbäck A; Olsson-Liljequist B; Eklund AE; Nord CE
    Scand J Infect Dis; 1996; 28(5):507-12. PubMed ID: 8953683
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro susceptibility and in vivo efficacy of antimicrobials in the treatment of Bacteroides fragilis-Escherichia coli infection in mice.
    Brook I
    J Infect Dis; 1989 Oct; 160(4):651-6. PubMed ID: 2677161
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.